Kura Oncology reported a net loss of $57.4 million for the first quarter of 2025, compared to a net loss of $49.5 million for the same period in 2024. The company's collaboration revenue significantly increased to $14.1 million from no revenue in the prior year, driven by its partnership with Kyowa Kirin. Research and development expenses rose to $56.0 million, reflecting increased clinical activities. The company ended the quarter with $658.2 million in cash, cash equivalents, and short-term investments, with a pro forma cash of $703.2 million after accounting for a $45 million milestone payment.

Kura Oncology reported positive topline results from its KOMET-001 registrational trial, achieving its primary endpoint, and announced alignment with the FDA and EMA on key aspects of the KOMET-017 protocol for potential U.S. accelerated approval. The company also reported a significant increase in collaboration revenue due to its partnership with Kyowa Kirin.

Kura Oncology reported a net loss of $54.4 million for the third quarter of 2024, compared to a net loss of $38.6 million for the third quarter of 2023. As of September 30, 2024, Kura had cash, cash equivalents and short-term investments of $455.3 million, which is expected to fund operations into 2027.

Kura Oncology reported a net loss of $50.8 million for the second quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $491.5 million as of June 30, 2024, which is expected to fund operations into 2027.

Kura Oncology reported a net loss of $49.5 million for the first quarter of 2024, compared to a net loss of $34.1 million for the same period in 2023. The company's cash, cash equivalents, and short-term investments totaled $527 million as of March 31, 2024, which is expected to fund operations into 2027.

Kura Oncology reported its fourth quarter and full year 2023 financial results, highlighting positive preliminary data from the KOMET-007 trial of ziftomenib in AML and the first patient dosed in the KOMET-008 trial. The company anticipates completing enrollment in the registration-directed trial of ziftomenib in NPM1-m AML by mid-2024 and has $570 million in pro forma cash providing runway into 2027.